新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » 百特完成对瑞典Gambro 40亿美元收购交易

百特完成对瑞典Gambro 40亿美元收购交易

来源:生物谷 2013-09-07 06:44

2013年9月7日讯 /生物谷BIOON/ --百特(Baxter)9月6日宣布,已完成对瑞典私人控股透析公司金宝(Gambro)的40亿美元收购交易。

此次收购,将有助于扩大百特透析产品线,获得全球各地更多的市场份额,同时将能够削减包括研发在内多领域成本。目前,百特已经在提供各种疾病的治疗药物,包括免疫系统疾病、血友病及其他疾病。

收购Gambro AB,对于百特来说是一个重要举措。因为福布斯指出,全球各地有超过200万患者需要某种形式的透析,而且这一数字还在以每年5%递增,可能是由于其他慢性疾病发生率增加的缘故。

去年,Gambro包括一些透析机在内的所有产品的销售总额为16亿美元,百特的销售额为138.9亿美元。肾脏科业务约占百特年收入的1/5。收购Gambro有望扩大百特肾脏科业务。

肾病科产品

百特是继德国费森尤斯医疗集团(Fresenius Medical Care AG)之后的全球第二大肾脏透析业务供应商,Gambro排名第三。根据彭博社汇编数据,百特去年的年收入为139亿美元,肾脏科产品约占18%。

Gambro去年以26.3亿美元的价格,将其CaridianBCT血液学仪器业务及债务,出售给了日本最大的医疗设备制造商泰尔茂株式会社(Terumo)。

关于瑞典金宝(Gambro)

Gambro 是一家全球性医疗技术公司,专注于研发、生产、制造用于急慢性患者肾脏和肝脏透析治疗、骨髓瘤肾透治疗以及其他体外治疗产品的领军者。该公司于1964年成立于瑞典兰德,创始人是决心开发并提供世界上首个人工肾脏之一的实业家Holger Crafoord,目前有 7500 名员工,在 9 个国家/地区拥有13处生产基地,产品在 100 多个国家/地区都有销售。(生物谷Bioon.com)


英文原文:Baxter Completes Acquisition of Gambro AB and Enhances Global Leadership in Renal Therapies

Baxter International Inc. (NYSE: BAX) today announced that the company has successfully completed the acquisition of Gambro AB, a privately held global medical technology company and leader in dialysis products based in Lund, Sweden. The transaction further enhances Baxter's global renal leadership and provides the company with a comprehensive product and therapies portfolio to meet the needs of patients in the large and growing dialysis market.

''The combination of these two respected renal leaders - Baxter and Gambro - will enable Baxter to better serve healthcare providers and patients through a collective offering of innovative renal products and therapies,'' said Robert L. Parkinson, Jr., chairman and chief executive officer of Baxter. ''Together, we will advance the state of dialysis care for patients with kidney disease worldwide.''

The acquisition provides a number of long-term growth opportunities for Baxter around the world. With a broad and complementary dialysis product portfolio and global footprint, Baxter can accelerate product sales in established markets such as Europe, where Gambro has an extensive presence. Baxter will also expand Gambro's reach in high-growth regions of Latin America and Asia-Pacific, where Baxter has steadily grown its peritoneal dialysis (PD) business. In addition, Baxter will build upon its core portfolio and pipeline of investigational home hemodialysis (HD) and automated PD systems by adding Gambro's dialyzers, devices and dialysis solutions, highly innovative and next-generation monitors, and acute therapies to treat patients with serious kidney, liver and lung conditions.

Brik Eyre has been named president of the combined Renal business and has been elected a corporate officer of Baxter by the company's Board of Directors. In his role, he will report to Robert M. Davis, president of Baxter's Medical Products business. Eyre joined Baxter in 2008 and previously served as the general manager of U.S. Medication Delivery. Prior to this role, Eyre served as general manager for Baxter's BioPharma Solutions business.

The total cash consideration for the transaction was approximately $3.9 billion USD. The transaction was financed through a combination of cash generated from overseas operations and debt issuances. The impact of the acquisition was included in Baxter's third quarter and full-year 2013 guidance.

About Baxter

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

This release includes forward-looking statements concerning Baxter's acquisition of Gambro AB and outlook for 2013. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the company's ability to successfully integrate Gambro, realize the anticipated benefits from the acquisition in the amounts and at the times expected and generate the sales included in the company's outlook for 2013; demand for and market acceptance of new and existing products; actions of regulatory bodies and other governmental authorities; changes to applicable laws and regulations; product development risks; product quality or patient safety concerns; the impact of global economic conditions on the company and its customers and suppliers; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库